Pfizer, Inc. (PFE) Shares Sold by Palo Capital Inc.
Palo Capital Inc. cut its position in shares of Pfizer, Inc. (NYSE:PFE) by 31.7% during the third quarter, Holdings Channel reports. The firm owned 15,742 shares of the biopharmaceutical company’s stock after selling 7,306 shares during the period. Palo Capital Inc.’s holdings in Pfizer were worth $533,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. Nelson Roberts Investment Advisors LLC increased its stake in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares in the last quarter. Tuttle Tactical Management LLC purchased a new stake in shares of Pfizer during the second quarter worth approximately $117,000. Gierl Augustine Investment Management Inc increased its stake in shares of Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares in the last quarter. Delphi Private Advisors LLC increased its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares in the last quarter. Finally, Lipe & Dalton purchased a new stake in shares of Pfizer during the second quarter worth approximately $152,000. 68.39% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.25% during midday trading on Friday, hitting $32.52. The company had a trading volume of 20,291,186 shares. Pfizer, Inc. has a one year low of $28.25 and a one year high of $37.39. The stock has a market capitalization of $197.34 billion, a price-to-earnings ratio of 32.65 and a beta of 0.91. The stock’s 50-day moving average price is $32.41 and its 200-day moving average price is $33.71.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by $0.01. The company earned $13.05 billion during the quarter, compared to the consensus estimate of $13.05 billion. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The company’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. Analysts predict that Pfizer, Inc. will post $2.42 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Investors of record on Friday, February 3rd will be paid a $0.32 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.30. This represents a $1.28 annualized dividend and a dividend yield of 3.94%. The ex-dividend date of this dividend is Wednesday, February 1st. Pfizer’s payout ratio is 106.20%.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The correct version of this piece can be read at http://www.dailypolitical.com/2017/01/13/pfizer-inc-pfe-shares-sold-by-palo-capital-inc.html.
PFE has been the subject of a number of research reports. Atlantic Securities set a $35.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Thursday, November 3rd. Sanford C. Bernstein set a $36.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, November 1st. Argus reiterated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Tuesday, October 4th. Bank of America reiterated a “buy” rating and issued a $40.00 price objective on shares of Pfizer in a research report on Tuesday, September 27th. Finally, Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price objective for the company. in a research report on Thursday, October 13th. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $37.30.
In other Pfizer news, insider Anthony J. Maddaluna sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the sale, the insider now directly owns 112,087 shares in the company, valued at $3,698,871. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the company’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $30.05, for a total value of $552,619.50. Following the sale, the insider now owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.